Ligand Pharmaceuticals Incorporated LGND announces the signing of a
global license agreement with Azure Biotech for the development of a novel
formulation of lasofoxifene targeting an underserved market in women's health.
Under the terms of the agreement, Ligand is entitled to receive $2.7 million
in potential development and regulatory milestones and a 5% royalty on future
net sales. Also under this agreement, Ligand retains rights to the oral
formulation originally developed by Pfizer.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in